A survey of chronic hepatitis B patient management practices in the EU.

StephenW

J Viral Hepat. 2010 May 4. [Epub ahead of print]

A survey of chronic hepatitis B patient management practices in the European
Union.

Berg T, Benhamou Y, Calleja JL, Levrero M, Johnson W, Ellis N.
Sektion Hepatologie, Klinik für Gastroenterologie und Rheumatologie,
Universitätsklinikum Leipzig, Leipzig, Germany.


Abstract

Summary. The current study sought to evaluate the characteristics of chronic
hepatitis B virus (HBV) infection and current management practices in the
European Union by surveying physician and patient records. A detailed survey
of physician practices and management of patients with CHB was conducted
between July and October 2006 in France, Germany, Italy and Spain. A total of
200 physicians participated in the survey, and data were collected from 2023
patients with chronic HBV infection. Most patients were men (69%), who had
hepatitis B e antigen (HBeAg)-negative disease (64%), and demonstrated
evidence of significant disease [53%; moderate fibrosis (35%), compensated
cirrhosis (14%), or decompensated cirrhosis (4%)]. Among the 1665
HBV-monoinfected patients surveyed, 1184 (71%) were currently receiving
treatment for chronic HBV infection. At treatment initiation, 70% of
HBeAg-positive patients had both pretreatment serum HBV DNA levels </=9
log(10) copies/mL and alanine aminotransferase (ALT) levels>/=2 x the upper
limit of normal (ULN), and 81% of HBeAg-negative patients had HBV DNA levels
of </=7 log(10) copies/mL. Among untreated patients, HBV DNA levels </=5
log(10,) ALT levels <2 x ULN, and mild or no liver fibrosis were present in
48% and 84% of HBeAg-positive and HBeAg-negative patients, respectively. In
conclusion, the majority of European patients with CHB surveyed were HBeAg
negative, Caucasian, men, and presented with significant histologic liver
disease. At treatment initiation, most HBeAg-positive patients had
pretreatment serum HBV DNA levels </=9 log(10) copies/mL and ALT levels>/=2 x
ULN, while the HBeAg-negative patients had HBV DNA levels </=7 log(10)
copies/mL.

PMID: 20487257 [PubMed - as supplied by publisher]



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

guixiaogang

　　进行的一项调查显示,慢性乙型肝炎病人管理实践的欧盟。
　　病毒性Hepat[五月四日。到2010年出版前Epub。)
　　
　　进行的一项调查显示,慢性乙型肝炎病人管理实践的欧洲
　　工会。
　　
　　不,Benhamou人质,Calleja杰,Levrero M,约翰逊,埃利斯N。
　　Sektion Hepatologie,Klinik Gastroenterologie和Rheumatologie皮毛,
　　德国莱比锡Universitatsklinikum莱比锡。
　　
　　
　　摘要
　　
　　总结。当前的研究旨在评估特征的慢性
　　乙型肝炎病毒(HBV)感染和现有的管理实践
　　欧盟通过测量医师和病人的病历。一份详细的问卷调查
　　医师实践和管理的,但很少有抗病毒能力
　　2006年7月到10月间在法国、德国、意大利和西班牙。共有
　　医生参与调查的200,数据收集912
　　慢性乙肝病毒感染的患者。大多数男性(69%),谁有
　　乙型肝炎e抗原(HBeAg)-negative疾病(64%),并展示
　　重大疾病的证据(53%;中度纤维化(35%),得到补偿
　　肝硬化(14%)、或失代偿肝硬化(4%)]。在1665
　　HBV-monoinfected患者中,93(71%)被接收
　　慢性HBV感染的治疗。在治疗开始,70%的
　　HBeAg-positive患者血清乙肝病毒DNA水平都预处理< / 9
　　日志(10)拷贝/ mL,谷丙转氨酶(谷丙转氨酶)层次>(= 2×上
　　正常的(ULN限制),81%的HBeAg-negative患者的病毒DNA水平
　　《/ = 7日志(10)拷贝/ mL。在治疗病人,病毒DNA水平< / = 5)
　　日志(10),谷丙转氨酶< 2×ULN、轻或不在场的肝纤维化
　　HBeAg-positive 48%,84%的病人,分别HBeAg-negative和。在
　　结论,大多数的欧洲,但很少有抗病毒能力参与HBeAg
　　消极的,白人,男,呈现显著组织学肝脏
　　疾病。在治疗开始,大多数HBeAg-positive患者
　　预处理血清乙肝病毒DNA水平< / = 9日志(10)拷贝/ mL,谷丙转氨酶>(= 2个
　　ULN,而HBeAg-negative患者病毒DNA水平< / = 7日志(10)。
　　复制/ mL。
　　
　　PMID:20487257[公共医学-提供出版商]